Cellectar Biosciences (formerly Novelos Therapeutics) is a clinical biopharmaceutical company that focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its products include proprietary phospholipid ether (PLE) platform, for the delivery of molecules and targeting of tumor cells; Iopofosine, a small-molecule phospholipid drug conjugate (PDC) for delivering radioisotope directly to cancer cells; etc.